Document Type
Article
Publication Date
1-1-2010
Abstract
Atypical antipsychotics have become a widely utilized component of the bipolar disorder treatment armamentarium, with approximately 45% of bipolar patients prescribed atypicals. Over the last decade all atypical drugs except for clozapine have received a Food and Drug Administration (FDA) bipolar indication. In October 2008, the FDA approved quetiapine XR monotherapy for the treatment of acute depressive episodes of bipolar disorder and acute manic or mixed episodes in bipolar I disorder based on two placebo-control trials. Quetiapine was also approved as adjunct therapy with lithium and divalproex for the treatment of acute manic or mixed episodes as well as maintenance of bipolar I disorder. In contrast to immediate release quetiapine which may require a twice-daily regimen, the XR formulation is intended for once-daily administration. This drug profile of quetiapine XR will address chemistry, pharmacodynamics, pharmacokinetics, metabolism, safety and tolerability and clinical trials in bipolar disorder. © 2010 Al Jurdi et al, publisher and licensee Dove Medical Press Ltd.
Keywords
bipolar disorder, quetiapine XR
Language
English
Publication Title
Neuropsychiatric Disease and Treatment
Rights
© The Author(s) 2010. This is an open access article under the CC BY-NC license (https://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Recommended Citation
Al Jurdi R, Dixit LA, Sajatovic M. Role of extended release quetiapine in the management of bipolar disorders. Neuropsychiatr Dis Treat. 2010;6(1):29-35. https://doi.org/10.2147/NDT.S4903
Manuscript Version
Final Publisher Version